Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Cupid has been allocated approximately 23.4 million units of female condoms per year
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
